{"schema_version":"secwatch.filing_event.v1","accession":"0001096906-22-002280","form_type":"8-K","ticker":"AXIM","cik":"0001514946","company_name":"AXIM BIOTECHNOLOGIES, INC.","filed_at":"2022-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.988249+00:00","generated_at":"2026-06-23T08:48:27.869416+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AXIM signs exclusive global licensing deal with Verséa for dry eye diagnostic tests","bullets":["Five-year License and Distribution Agreement with Verséa for global sale of AXIM's point-of-care ocular diagnostics.","Three tests included: IgE (allergy), Lactoferrin (dry eye), and MMP-9 (inflammation); IgE and Lactoferrin are FDA-cleared.","Verséa plans to launch IgE and Lactoferrin tests at 2022 AAO and Optometry conferences; MMP-9 in 18–24 months.","Verséa must meet annual minimum sales commitments; no upfront or milestone payments disclosed.","CEO Huemoeller says deal marks transition from development-stage to revenue-generating healthcare organization."],"urls":{"canonical":"https://secwatch.observer/filing/0001096906-22-002280","json":"https://secwatch.observer/filing/0001096906-22-002280.json","markdown":"https://secwatch.observer/filing/0001096906-22-002280.md","text":"https://secwatch.observer/filing/0001096906-22-002280.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514946/000109690622002280/0001096906-22-002280-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514946/000109690622002280/axim-20210915.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T08:48:27.869416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}